SG10201608813PA - Quinazoline derivatives as raf kinase modulators and methods of use thereof - Google Patents

Quinazoline derivatives as raf kinase modulators and methods of use thereof

Info

Publication number
SG10201608813PA
SG10201608813PA SG10201608813PA SG10201608813PA SG10201608813PA SG 10201608813P A SG10201608813P A SG 10201608813PA SG 10201608813P A SG10201608813P A SG 10201608813PA SG 10201608813P A SG10201608813P A SG 10201608813PA SG 10201608813P A SG10201608813P A SG 10201608813PA
Authority
SG
Singapore
Prior art keywords
methods
raf kinase
quinazoline derivatives
kinase modulators
modulators
Prior art date
Application number
SG10201608813PA
Inventor
Sunny Abraham
Shripad S Bhagwat
Brian T Campbell
Qi Chao
Raffaella Faraoni
Mark W Holladay
Andiliy G Lai
Martin W Rowbottom
Eduardo Setti
Kelly G Sprankle
Original Assignee
Ambit Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambit Biosciences Corp filed Critical Ambit Biosciences Corp
Publication of SG10201608813PA publication Critical patent/SG10201608813PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/93—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
SG10201608813PA 2008-03-17 2009-03-17 Quinazoline derivatives as raf kinase modulators and methods of use thereof SG10201608813PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6976308P 2008-03-17 2008-03-17
US11050808P 2008-10-31 2008-10-31

Publications (1)

Publication Number Publication Date
SG10201608813PA true SG10201608813PA (en) 2016-12-29

Family

ID=40852165

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201608813PA SG10201608813PA (en) 2008-03-17 2009-03-17 Quinazoline derivatives as raf kinase modulators and methods of use thereof
SG2013046388A SG191678A1 (en) 2008-03-17 2009-03-17 Quinazoline derivatives as raf kinase modulators and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2013046388A SG191678A1 (en) 2008-03-17 2009-03-17 Quinazoline derivatives as raf kinase modulators and methods of use thereof

Country Status (23)

Country Link
US (5) US8618289B2 (en)
EP (3) EP3147281A1 (en)
JP (1) JP5542793B2 (en)
KR (2) KR101713501B1 (en)
CN (2) CN102026985B (en)
AU (1) AU2009226136B2 (en)
BR (1) BRPI0906186A2 (en)
CA (2) CA2718123C (en)
DK (2) DK2947072T3 (en)
EA (1) EA019350B1 (en)
ES (2) ES2610989T3 (en)
HK (2) HK1151525A1 (en)
HU (2) HUE032873T2 (en)
IL (1) IL207793A (en)
MX (1) MX2010010172A (en)
MY (1) MY161576A (en)
NZ (1) NZ587907A (en)
PL (2) PL2947072T3 (en)
PT (2) PT2947072T (en)
SG (2) SG10201608813PA (en)
SI (2) SI2947072T1 (en)
WO (1) WO2009117080A1 (en)
ZA (1) ZA201006524B (en)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200940540A (en) * 2008-02-29 2009-10-01 Array Biopharma Inc RAF inhibitor compounds and methods of use thereof
WO2009111280A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
JP2011513329A (en) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド Imidazo [4,5-b] pyridine derivatives used as RAF inhibitory compounds
CN102149712A (en) * 2008-02-29 2011-08-10 阵列生物制药公司 Pyrazole [3, 4-b] pyridine Raf inhibitors
HUE032873T2 (en) 2008-03-17 2017-11-28 Ambit Biosciences Corp 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea as raf kinase modulator in the treatment of cancer diseases
CA2752265A1 (en) * 2009-02-17 2010-08-26 Boehringer Ingelheim International Gmbh Pyrimido [5,4-d] pyrimidine derivatives for the inhibition of tyrosine kinases
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
CN102639539B (en) * 2009-11-05 2014-12-10 埃姆比特生物科学公司 Process for the preparation of imidazo[2,1-b][1,3]benzothiazole derivatives
JP5787977B2 (en) 2010-04-08 2015-09-30 レスピバート・リミテツド P38 MAP kinase inhibitor
EP2582700B1 (en) 2010-06-17 2016-11-02 Respivert Limited Respiratory formulations containing p38 mapk inhibitors
SI2712358T1 (en) 2011-05-13 2017-03-31 Array Biopharma, Inc. Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
ES2725790T3 (en) 2011-08-26 2019-09-27 Neupharma Inc Some chemical entities, compositions, and methods
CN108794411B (en) 2011-09-14 2022-06-07 润新生物公司 Certain chemical entities, compositions, and methods
EP2578582A1 (en) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
BR112014007694B1 (en) 2011-10-03 2022-09-27 Respivert Limited 1-(3-(TERT-BUTYL)-1-(P-TOLYL)-1H-PYRAZOL-5-IL)-3-(4-((2-(PHENYLAMINO) PYRIMIDIN-4-YL)OXY) COMPOUNDS NAFTALEN-1-IL)UREA, ITS USES, COMPOSITION AND PHARMACEUTICAL FORMULATION INCLUDING THE SAME
CN108047201A (en) 2011-11-14 2018-05-18 亚尼塔公司 Uracil derivative as AXL and c-MET kinase inhibitors
WO2013112950A2 (en) * 2012-01-25 2013-08-01 Neupharma, Inc. Certain chemical entities, compositions, and methods
EP2626073A1 (en) * 2012-02-13 2013-08-14 Harmonic Pharma Compound for use in the prevention and/or treatment of a neurogenerative disease or a disease involving an activation of phosphodiesterase-4 (PDE4)
GB201214750D0 (en) 2012-08-17 2012-10-03 Respivert Ltd Compounds
JP2015530378A (en) * 2012-08-29 2015-10-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ DDR2 inhibitors for the treatment of osteoarthritis
US9688635B2 (en) 2012-09-24 2017-06-27 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN103102315B (en) * 2012-11-01 2016-01-20 云南大学 A kind of Quinazoline arylurea and its production and use
US9725421B2 (en) 2012-11-12 2017-08-08 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
US9732063B2 (en) 2012-11-16 2017-08-15 Respivert Limited Kinase inhibitors
US9353122B2 (en) * 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9695184B2 (en) 2013-02-15 2017-07-04 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
WO2014164648A2 (en) * 2013-03-11 2014-10-09 Cephalon, Inc. Solid state forms of a quinazoline derivative and its use as a braf inhibitor
US20160016934A1 (en) 2013-03-14 2016-01-21 Respivert Limited Kinase inhibitors
WO2014162121A1 (en) * 2013-04-02 2014-10-09 Topivert Pharma Limited Kinase inhibitors based upon n-alkyl pyrazoles
CN103159685A (en) * 2013-04-11 2013-06-19 苏州立新制药有限公司 Preparation method of 4-chloro-6, 7-di(2-methoxyl ethoxyl) quinazoline
US9771333B2 (en) 2013-11-20 2017-09-26 Signalchem Lifesciences Corp. Quinazoline derivatives as TAM family kinase inhibitors
SG11201607058PA (en) 2014-02-14 2016-10-28 Respivert Ltd Aromatic heterocyclic compounds as antiinflammatory compounds
SG11201608303QA (en) 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
EP3139927A4 (en) * 2014-05-06 2017-12-13 The Regents of The University of California Wound healing using braf inhibitors
CN104892530A (en) * 2015-05-27 2015-09-09 烟台大学 Diaryl urea compound containing quinazoline structure as well as preparation method and application thereof
CN104892529A (en) * 2015-05-27 2015-09-09 烟台大学 Thiourea compound containing quinazoline structure as well as preparation method and application of thiourea compound
EA035049B1 (en) * 2015-07-16 2020-04-22 Аррэй Байофарма Инк. SUBSTITUTED PYRAZOLO[1,5-a]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
WO2017062500A2 (en) 2015-10-05 2017-04-13 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
EP3548007A4 (en) 2016-12-01 2020-08-12 Ignyta, Inc. Methods for the treatment of cancer
EP3571203B1 (en) 2017-01-18 2023-06-07 Array BioPharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
CN108530455B (en) * 2017-03-01 2021-01-12 北京赛特明强医药科技有限公司 Urea substituted aromatic ring connecting dioxane and quinazoline compound or medicinal salt or hydrate and application as tyrosine kinase inhibitor
CN106928069B (en) * 2017-03-21 2019-03-19 上海玉函化工有限公司 A kind of preparation method of 4,5- bis- (2- methoxy ethoxy) -2- ethyl nitrobenzoate
EP3600294A4 (en) 2017-03-23 2020-08-26 Clavius Pharmaceuticals, LLC Tri-substituted imidazoles for the inhibition of tgf beta and methods of treatment
CN107501283B (en) 2017-09-13 2020-06-02 北京师范大学 Preparation of substituted arylmethyl hetero-substituted anilino ethylene glycol ether cycloquinazoline and application of tumor treatment drug
CN109721551B (en) * 2017-10-30 2022-09-20 上海北卡医药技术有限公司 Preparation method of 3, 4-dihydro-7-methoxy-4-oxoquinazolin-6-ol acetate
CN109721552B (en) * 2017-10-30 2022-09-20 上海北卡医药技术有限公司 Preparation method of gefitinib
US11524963B2 (en) 2018-01-18 2022-12-13 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors
TWI802635B (en) 2018-01-18 2023-05-21 美商亞雷生物製藥股份有限公司 Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
JP6997876B2 (en) 2018-01-18 2022-02-04 アレイ バイオファーマ インコーポレイテッド Substituted pyrazolyl [4,3-C] pyridine compound as a RET kinase inhibitor
KR102436669B1 (en) 2018-02-11 2022-08-25 베이징 사이텍-엠큐 파마슈티컬즈 리미티드 Urea-substituted aromatic ring-linked dioxinoquinoline compound, preparation method and use thereof
CN108358798A (en) * 2018-02-12 2018-08-03 黑龙江鑫创生物科技开发有限公司 A kind of method of micro passage reaction synthesis Tarceva intermediate
WO2019241787A1 (en) * 2018-06-15 2019-12-19 The Regents Of The University Of Colorado A Body Corporate Novel cyclic gmp-amp synthase (cgas) inhibitors and their method of use
CN110862398B (en) * 2018-08-27 2021-04-06 北京赛特明强医药科技有限公司 Urea substituted aromatic ring-linked dioxane quinazoline or quinoline compound, composition and application thereof
EP3849536A4 (en) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
CN109553581B (en) * 2018-09-25 2022-01-25 广州六顺生物科技股份有限公司 Substituted urea compounds, pharmaceutically acceptable salts or solvates thereof, uses thereof, medicaments and pharmaceutical compositions
TW202043225A (en) * 2019-01-25 2020-12-01 英屬開曼群島商百濟神州有限公司 Stable solid dispersion of a b-raf kinase dimer inhibitor, methods of preparation, and uses therefor
ES2952251T3 (en) * 2019-02-12 2023-10-30 Lutris Pharma Ltd Use of topical BRaf inhibitor compositions for the treatment of radiation dermatitis
EP4073044A1 (en) * 2019-12-10 2022-10-19 F. Hoffmann-La Roche AG New braf inhibitors as paradox breakers
WO2022159835A1 (en) 2021-01-25 2022-07-28 Halia Therapeutics, Inc. Nek7 inhibitors
CN113254860B (en) * 2021-06-04 2022-03-22 南京航空航天大学 Method for calculating neutron flux of reactor core grid cells

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) * 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
DE3209472C2 (en) * 1982-03-16 1984-05-17 Degussa Ag, 6000 Frankfurt Process for the preparation of 3-oxonitriles and new 3-oxonitriles
HU196714B (en) 1984-10-04 1989-01-30 Monsanto Co Process for producing non-aqueous composition comprising somatotropin
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
JPS6296479A (en) 1985-10-23 1987-05-02 Shionogi & Co Ltd Polyfluoroalkylisoxazolylamine
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IT1229203B (en) * 1989-03-22 1991-07-25 Bioresearch Spa USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (en) 1990-04-17 1994-11-18 Eurand Int METHOD FOR THE TARGETED AND CONTROLLED DELIVERY OF DRUGS IN THE INTESTINE AND PARTICULARLY IN THE COLON
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) * 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
IT1270594B (en) * 1994-07-07 1997-05-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
US5759542A (en) * 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
AU6242096A (en) 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (en) * 1995-09-18 1999-06-23 株式会社資生堂 Delayed release microsphere of drug
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
WO1997017329A1 (en) * 1995-11-07 1997-05-15 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
TW345603B (en) * 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
AU722289B2 (en) 1996-10-01 2000-07-27 Aptalis Pharmatech, Inc. Taste-masked microcapsule compositions and methods of manufacture
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ATE272394T1 (en) * 1996-10-31 2004-08-15 Takeda Chemical Industries Ltd DELAYED RELEASE PREPARATION
US6131570A (en) * 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
ATE233088T1 (en) 1996-12-20 2003-03-15 Takeda Chemical Industries Ltd METHOD FOR PREPARING A DELAYED RELEASE COMPOSITION
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US20070244120A1 (en) * 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6048736A (en) * 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (en) 1998-05-16 1999-12-06 허영섭 Biodegradable polymer microspheres capable of continuously controlled controlled release and preparation method thereof
ATE294796T1 (en) 1998-10-08 2005-05-15 Astrazeneca Ab QUINAZOLINE DERIVATIVES
HU230789B1 (en) * 1999-01-22 2018-05-02 Kyowa Hakko Kirin Co Quinoline derivatives and quinazoline derivatives, pharmaceutical compositions containing them and their use
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6271359B1 (en) * 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US7135466B2 (en) * 1999-12-24 2006-11-14 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives and drugs containing the same
CA2420535A1 (en) 2000-08-30 2002-03-07 Mary Tanya Am Ende Sustained release formulations for growth hormone secretagogues
TWI304061B (en) * 2000-10-20 2008-12-11 Eisai R&D Man Co Ltd Nitrogen-containing aromatic ring derivatives
EP1382604B1 (en) * 2001-04-27 2005-12-28 Kirin Beer Kabushiki Kaisha Quinoline derivative having azolyl group and quinazoline derivative
CN100415720C (en) * 2001-06-22 2008-09-03 麒麟医药株式会社 Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor and medicinal composition containing the same
EP2277867B1 (en) 2002-07-15 2012-12-05 Symphony Evolution, Inc. Compounds, pharmaceutical compositions thereof and their use in treating cancer
EP2609919A3 (en) * 2003-09-26 2014-02-26 Exelixis, Inc. c-Met modulators and methods of use
US20050084835A1 (en) 2003-10-16 2005-04-21 The Singing Machine Company, Inc. Karaoke system with built-in camera
US20050197371A1 (en) * 2003-11-13 2005-09-08 Ambit Biosciences Corporation Urea derivatives as PDGFR modulators
EP2942349A1 (en) 2004-12-23 2015-11-11 Deciphera Pharmaceuticals, LLC Enzyme modulators and treatments
US7576090B2 (en) * 2004-12-27 2009-08-18 4Sc Ag Benzazole analogues and uses thereof
EP1746096A1 (en) * 2005-07-15 2007-01-24 4Sc Ag 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
EP1966159A2 (en) 2005-12-22 2008-09-10 AstraZeneca AB Chemical compounds
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
US20070265258A1 (en) 2006-03-06 2007-11-15 Ruiping Liu Quinazoline derivatives as phosphodiesterase 10 inhibitors
JP2009532450A (en) 2006-04-05 2009-09-10 アストラゼネカ アクチボラグ Compound
US20090163525A1 (en) 2006-04-05 2009-06-25 Astrazeneca Ab Substituted quinazolines with anti-cancer activity
JP5415264B2 (en) 2006-06-30 2014-02-12 ドイスコベルク コーポレーション Detectable nucleic acid tag
MX2009004019A (en) 2006-10-19 2009-06-19 Signal Pharm Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors.
WO2008051493A2 (en) 2006-10-19 2008-05-02 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
HUE032873T2 (en) 2008-03-17 2017-11-28 Ambit Biosciences Corp 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea as raf kinase modulator in the treatment of cancer diseases

Also Published As

Publication number Publication date
CN106146484A (en) 2016-11-23
ZA201006524B (en) 2013-02-27
DK2947072T3 (en) 2017-01-23
DK2268623T3 (en) 2015-06-29
IL207793A0 (en) 2010-12-30
PL2268623T3 (en) 2015-10-30
HK1216100A1 (en) 2016-10-14
US8618289B2 (en) 2013-12-31
EP2268623B9 (en) 2018-02-28
AU2009226136B2 (en) 2013-08-15
CA2718123A1 (en) 2009-09-24
AU2009226136A1 (en) 2009-09-24
KR101713501B1 (en) 2017-03-07
EP2947072B1 (en) 2016-11-09
US10053430B2 (en) 2018-08-21
EP2947072A1 (en) 2015-11-25
US20140045868A1 (en) 2014-02-13
PT2947072T (en) 2016-12-06
CA2718123C (en) 2017-08-22
ES2547406T3 (en) 2015-10-06
EP2268623A1 (en) 2011-01-05
SI2268623T1 (en) 2016-01-29
CN102026985B (en) 2016-07-06
WO2009117080A8 (en) 2010-11-04
US20160199375A1 (en) 2016-07-14
CN102026985A (en) 2011-04-20
NZ587907A (en) 2012-09-28
HK1151525A1 (en) 2012-02-03
JP2011529021A (en) 2011-12-01
US20170298029A1 (en) 2017-10-19
EP3147281A1 (en) 2017-03-29
US8969587B2 (en) 2015-03-03
HUE025197T2 (en) 2016-02-29
BRPI0906186A2 (en) 2015-09-22
MX2010010172A (en) 2010-11-25
KR20110003340A (en) 2011-01-11
SG191678A1 (en) 2013-07-31
ES2610989T3 (en) 2017-05-04
KR101601997B1 (en) 2016-03-17
EA201071089A1 (en) 2011-04-29
EA019350B1 (en) 2014-03-31
MY161576A (en) 2017-04-28
EP2268623B1 (en) 2015-05-06
IL207793A (en) 2014-11-30
US20110118245A1 (en) 2011-05-19
PL2947072T3 (en) 2017-05-31
WO2009117080A1 (en) 2009-09-24
CA2972138A1 (en) 2009-09-24
KR20160012243A (en) 2016-02-02
US9730937B2 (en) 2017-08-15
JP5542793B2 (en) 2014-07-09
US9320739B2 (en) 2016-04-26
PT2268623E (en) 2015-09-17
US20150246042A1 (en) 2015-09-03
SI2947072T1 (en) 2017-03-31
HUE032873T2 (en) 2017-11-28

Similar Documents

Publication Publication Date Title
HK1151525A1 (en) Quinazoline derivatives as raf kinase modulators and methods of use thereof raf
HK1254895A1 (en) Benzylbenzene derivatives and methods of use
IL214768A0 (en) Jak kinase modulating quinazoline derivatives and methods of use thereof
HK1160119A1 (en) Kinase inhibitors and methods of use
EP2252293A4 (en) Kinase inhibitors and methods of use
EG27167A (en) Microemulsifiers and methods of making and using same
HK1172896A1 (en) Compounds and methods of use
HK1161094A1 (en) Compounds and methods of use
IL211549A0 (en) Aminotriazolopyridines and their use as kinase inhibitors
IL213596A0 (en) Heterocyclic compounds and methods of use
HK1147254A1 (en) 5-anilinoimidazopyridines and methods of use 5-
EP2114983A4 (en) Axl tyrosine kinase inhibitors and methods of making and using the same
HK1149933A1 (en) Diazacarbazoles and methods of use
IL209548A0 (en) Diazacarbazoles and methods of use
EP2242854A4 (en) Sirna compounds and methods of use thereof
ZA201000183B (en) Quinazolinone compounds and methods of use thereof
IL206125A0 (en) Azaindolizines and methods of use
EP2376083A4 (en) Quinazoline inhibitors of bace 1 and methods of using
EP2328603A4 (en) Derivatives of apf and methods of use